Brief: Transgene SA Plans To Commence A Randomized Phase Ii Trial In Head And Neck Cancer With Tg4050 In 2024
20/09/2023 16:52
Sept 20 (Reuters) - Transgene SA TRNG.PA :
* TRANSGENE SA: PLANS TO COMMENCE A RANDOMIZED PHASE II
TRIAL IN
HEAD AND NECK CANCER WITH TG4050 IN 2024
* TRANSGENE SA - EXTENDED FINANCIAL VISIBILITY SECURED UNTIL
END
OF 2024 THROUGH A NON-DILUTIVE FINANCING PROVIDED BY MAJOR
SHAREHOLDER INSTITUT MÉRIEUX
* TRANSGENE SA - PLANS TO COMMENCE A RANDOMIZED PHASE II
TRIAL IN
HEAD AND NECK CANCER WITH TG4050 IN 2024
Source text for Eikon: ID:nBw7B6XkCa
Further company coverage: TRNG.PA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Transgene SA
See all newsFrance's Transgene H1 operating income falls on lower tax credit
Transgene jumps 20% on positive cancer vaccine data in early trial
Brief: Transgene & NEC Bio Sign License Agreement To Prepare Next Steps Of Development Of TG4050 In Head & Neck Cancer
Brief: Transgene SA Says Myvac Platform To Initiate Phase 1 Trial In Second Indication In 2026
France's Transgene 2025 net loss widens on higher financial costs